ArticleNanotheranostics2018
Functionalised Carbon Nanotubes Enhance Brain Delivery of Amyloid-Targeting Pittsburgh Compound B (PiB)-Derived Ligands.
Article in Nanotheranostics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 72 citations in OpenAlex.
- Phytochemical Nanoparticles for the Treatment of Neurological Disorders.Phytochemical analysis : PCA · 2025Review
- A Significant Prospective on Nanorobotics in Precision Medicine and Therapeutic Interventions.Pharmaceutical nanotechnology · 2025Review
- Nanoparticles in CNS Therapeutics: Pioneering Drug Delivery Advancements.Current pharmaceutical design · 2025Review
- Radiosensitizing properties of dual-functionalized carbon nanostructures loaded with temozolomide.Beilstein journal of nanotechnology · 2025Article
- Advances in Alzheimer's disease control approaches via carbon nanotubes.Nanomedicine (London, England) · 2025Review
- Nanomaterials that Aid in the Diagnosis and Treatment of Alzheimer's Disease, Resolving Blood-Brain Barrier Crossing Ability.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- Multifunctional Nanocarriers for Alzheimer's Disease: Befriending the Barriers.Molecular neurobiology · 2024Review
- Functionalised Carbon Nanotubes: Promising Drug Delivery Vehicles for Neurovascular Disorder Intervention.AAPS PharmSciTech · 2023Review
- Review
- In Vivo Preclinical Assessment of β-Amyloid-Affine [International journal of molecular sciences · 2022Article
- Carbon Nanotubes: Current Perspectives on Diverse Applications in Targeted Drug Delivery and Therapies.Materials (Basel, Switzerland) · 2021Review
- Carbon Nanotubes: Smart Drug/Gene Delivery Carriers.International journal of nanomedicine · 2021Review
- Nano-Neurotheranostics: Impact of Nanoparticles on Neural Dysfunctions and Strategies to Reduce Toxicity for Improved Efficacy.Frontiers in pharmacology · 2021Review
- Current update on nanoplatforms as therapeutic and diagnostic tools: A review for the materials used as nanotheranostics and imaging modalities.Asian journal of pharmaceutical sciences · 2021Review
- Contrast Agents Delivery: An Up-to-Date Review of Nanodiagnostics in Neuroimaging.Nanomaterials (Basel, Switzerland) · 2019Review
- Neuronanomedicine: An Up-to-Date Overview.Pharmaceutics · 2019Review
- Nanoparticulate drug delivery systems for the treatment of neglected tropical protozoan diseases.The journal of venomous animals and toxins including tropical diseases · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder characterised by brain accumulation of toxic protein aggregates, including extracellular amyloid beta (Aβ) plaques, inflammation, neuronal death and progressive cognitive dysfunction. Current diagnostic modalities, based on cognitive tests, fail to detect early AD onset, thus emphasising the need to develop improved methods for pre-symptomatic disease detection. Building on the properties of the Pittsburgh Compound B (PiB), an Aβ-binding molecule suitable to use as positron emission tomography (PET) imaging agent, and aiming at using a more clinically available modality (like magnetic ressonance imaging, MRI), PiB derivatives have been conjugated to the macrocyclic chelator 1,4,7-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane (DO3A) monoamide. However, these derivatives do not readily cross the highly selective blood-brain barrier (BBB). Taking advantage of the capacity of functionalised carbon nanotubes (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.